CD274 and non-small cell lung carcinoma: Several anti-PD-1/PD-L1 inhibiting antibodies have been introduced as a second-line therapy for patients with advanced NSCLC or as a first-line therapy combined with chemotherapy for patients with squamous cell carcinoma (SCC) [7].